Prokarium
Develops engineered bacterial immunotherapies for cancer, led by ZH9 for non-muscle invasive bladder cancer.
prokarium.com ↗Why it's here
Reported positive interim data from its Phase 1/1b PARADIGM-1 trial of ZH9 in bladder cancer at AUA 2026 in May 2026.
source: prokarium.com- Focus
- Microbial immunotherapy
- Founded
- 2007
- Latest round
- Financing, $30M, Feb 2023
- London office
- London Bioscience Innovation Centre, 2 Royal College Street, London, Camden NW1 0NHsource: prokarium.com
- London presence
- HQsource: prokarium.com
- Area
- Camden
- Nearest station
- Mornington Crescent, 409 m
- Visas
- Licensed visa sponsor, listed as Prokarium Limitedsource: gov.uk
Verified 8 Oct 2026. How we verify · Suggest a fix